- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Shruti Agnihotri Highlights the Importance of Value-Based Neurologic Care for Post–COVID-19 Patients
Shruti Agnihotri, MD, associate professor at the University of Alabama Birmingham, discusses how value-based care can help patients who experience neurologic chronic disease states after COVID-19, in addition to patients with conditions like stroke and dementia.
Value-based care is important for patients who experience neurologic issues after COVID-19, as well as patients with stroke and dementia, says Shruti Agnihotri, MD, associate professor at the University of Alabama Birmingham.
Transcript
What role does value-based care play in neurological conditions?
Value-based care is very important in neurologic conditions—many different neurologic conditions, of course, in things like dementia, strokes—but I think it's also important in our post–COVID-19 patient population. At the heart of what we do so far for our post–COVID-19 patients is managing high blood pressure, diabetes; the chronic conditions, chronic states, which affect how the brain will function for these patients. I think, yes, there is a large role that value-based care or managed care can play in these patient care situations.
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More
